Key Takeaways Canagliflozin reduces the risk of sustained and adjudicated major kidney outcomes in patients with T2DM at high risk of cardiovascular events. Objective Study Type Participants To study the effect Canagliflozin on renal outcomes in patients with T2DM Randomised, Placebo-controlled trial 10,142 Synopsis A clinical study demonstrates that canagliflozin treatment is associated with a reduced risk of sustained loss of kidney function, attenuated eGFR decline, and a reduction in albuminuria, that gives a renoprotective effect in people with type 2 diabetes. This week's ' MED FACT ' discusses a clinical trial from The Lancet Diabetes & Endocrinology , “ Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials ”.
June, 2018. Authors : Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD;…
